Movement Disorders

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

Closing out his review of on-demand therapies for morning OFF episodes in Parkinson disease, Peter A. LeWitt, MD, shares practical advice for community neurologists.

Peter A. LeWitt, MD, discusses the use of sublingual apomorphine hydrochloride compared with its subcutaneous formulation in Parkinson disease.

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Expert insight on the mechanism of action and use of subcutaneous apomorphine hydrochloride in patients with Parkinson disease.

Peter A. LeWitt, MD, considers the mechanism of action and use of levodopa inhalation powder in patients with Parkinson disease.

The guideline updates previous recommendations for dopaminergic medications published in 2002, integrating new medications and formulations.

Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.

A panel of experts debate the disadvantages and side effects of apomorphine therapies for Parkinson’s disease.

A discussion on the use of apomorphine subcutaneous injections in managing Parkinson’s disease.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending November 13, 2021.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

A brief overview of clinically available on-demand therapies used to manage morning OFF episodes in patients with Parkinson disease.

Expert neurologist Peter A. LeWitt, MD, reflects on the challenges inherent in treating morning OFF episodes in patients with Parkinson disease.

Those who received an infusion of ABBV-951, consisting of foslevodopa/foscarbidopa, showed statistically significant increases in hours of ON time without troublesome dyskinesia compared with oral levodopa/carbidopa.

Twelve months after subthalamic deep brain stimulation, patients with and without RBD had MDS-UPDRS IV score decrease, MDS-UPDRS III MedOff decrease, and total LEDD decrease, with no between group difference.

Neurologists debate the use of levodopa inhalation powder in managing Parkinson’s disease.

Physicians discuss when to add on-demand therapies to Parkinson’s disease management.

Here's what is coming soon to NeurologyLive.